A panel of five circulating microRNAs as potential biomarkers for prostate cancer

Prostate

Volumn 72, Issue 13, 2012, Pages 1443-1452

  Chen, Zhang Hui ^a,b   Zhang, Guang Lin ^a   Li, Huan Rong ^a   Luo, Jin Dan ^a   Li, Zhong Xiang ^b   Chen, Ge Ming ^a   Yang, Jun ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

benign prostatic hyperplasia; biomarker; microRNA; principal component analysis; prostate cancer

Indexed keywords

MICRORNA; MICRORNA 1285; MICRORNA 16; MICRORNA 25; MICRORNA 30C; MICRORNA 346; MICRORNA 622; MICRORNA 940; MICRORNA LET 7C; MICRORNA LET 7E; MICRORNA U6; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHINESE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864877949     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22495     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z, Debre B,. A comparative study of prostate cancer detection and management in China and in France. Can J Urol 2009; 16 (1): 4472-4477.
3. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR,. Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008; 15 (3): 4056-4064.
4. Berthold DR, Sternberg CN, Tannock IF,. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23 (32): 8247-8252. (Pubitemid 46211562)
5. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C,. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60 (3 Suppl 1): 1-6.
6. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53 (1): 68-80. (Pubitemid 350166735)
7. Mazhar D, Waxman J,. Early chemotherapy in prostate cancer. Nat Clin Pract Urol 2008; 5 (9): 486-493.
8. Wilkinson S, Chodak GW,. Critical review of complementary therapies for prostate cancer. J Clin Oncol 2003; 21 (11): 2199-2210. (Pubitemid 46606370)
9. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
10. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL,. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model. Urology 1999; 54 (2): 220-224. (Pubitemid 29367241)
11. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V,. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001; 166 (3): 845-850. (Pubitemid 32750962)
12. Roehl KA, Antenor JA, Catalona WJ,. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol 2002; 168 (3): 922-925.
13. Klotz L,. Active surveillance for prostate cancer: A review. Curr Urol Rep 2010; 11 (3): 165-171.
14. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F,. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 2009; 55 (6): 1321-1330.
15. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ,. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94 (13): 981-990. (Pubitemid 34814727)
16. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
17. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
18. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54 (12): 1951-1960. (Pubitemid 352774027)
19. Jackson RJ, Standart N,. How do microRNAs regulate gene expression? Sci STKE 2007; 2007 (367): re1.
20. Lee RC, Feinbaum RL, Ambros V,. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75 (5): 843-854. (Pubitemid 24014542)
21. Huntzinger E, Izaurralde E,. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12 (2): 99-110.
22. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T,. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 2011; 59 (5): 671-681.
23. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K,. MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urol Oncol 2010; 28 (1): 4-13.
24. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2010; 128 (3): 608-616.
25. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P, Blelloch R,. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2010; 71 (2): 550-560.
26. Perkins CIMC, Wright WE, Young JL, editors. Cancer incidence and mortality in California by detailed race/ethnicity, 1988-1992. Sacramento, CA: Cancer Surveillance Section, Department of Health Services; 1995.
27. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK,. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer 2007; 110 (6): 1255-1263. (Pubitemid 47435596)
28. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S,. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 2010; 5 (10): e13735.
29. Li GZ, Bu HL, Yang MQ, Zeng XQ, Yang JY,. Selecting subsets of newly extracted features from PCA and PLS in microarray data analysis. BMC Genomics 2008; 9 (Suppl 2): S24.
30. Kloda JM, Dean PD, Maddren C, MacDonald DW, Mayes S,. Using principle component analysis to compare genetic diversity across polyploidy levels within plant complexes: An example from British Restharrows (Ononis spinosa and Ononis repens). Heredity (Edinb) 2008; 100 (3): 253-260. (Pubitemid 351282122)
31. de Haan JR, Wehrens R, Bauerschmidt S, Piek E, van Schaik RC, Buydens LM,. Interpretation of ANOVA models for microarray data using PCA. Bioinformatics 2007; 23 (2): 184-190. (Pubitemid 46189608)
32. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6130-6135. (Pubitemid 47037493)
33. Shi XB, Tepper CG, White RW,. MicroRNAs and prostate cancer. J Cell Mol Med 2008; 12 (5A): 1456-1465.
34. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J,. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16 (3): 206-216.
35. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ,. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009; 58 (10): 1375-1381.
36. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F,. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579-587.
37. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH,. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010; 3 (1): 28-47.
38. Gao W, Liu L, Lu X, Shu Y,. Circulating microRNAs: Possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer 2011; 12 (1): 14-17.
39. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H,. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28 (10): 1721-1726.
40. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-10518.
41. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ,. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106 (11): 4402-4407.
42. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Zen K, Zhang CY,. Expression profile of microRNAs in serum: A fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010; 56 (12): 1871-1879.
43. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT,. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (4): 423-433.
44. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M,. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108 (12): 5003-5008.
45. Esquela-Kerscher A, Slack FJ,. Oncomirs-MicroRNAs with a role in cancer. Nat Rev Cancer 2006; 6 (4): 259-269.
46. Shi XB, Tepper CG, deVere White RW,. Cancerous miRNAs and their regulation. Cell Cycle 2008; 7 (11): 1529-1538. (Pubitemid 351881316)
47. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH,. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69 (16): 6704-6712.
48. Tian S, Huang S, Wu S, Guo W, Li J, He X,. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun 2010; 396 (2): 435-439.